drugset / Trial / NCT05967884
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
Phase 2
Unknown
20 enrolled
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor positive (ER+) breast cancer.
Timeline
- Start
- 2023-08-04
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Dupilumab | Monoclonal antibody | 600 mg | Subcutaneous |